Why Malaysian Retail Investors Love Growth Stocks Under 10 – and the Hidden Trap
For many Malaysian retail investors, US tech and biotech stocks trading under US$10 look irresistibly “cheap”. With limited capital and easy access to international brokerages, it is tempting to assume that a low share price means lower risk and higher upside. In reality, price per share tells you almost nothing about valuation or safety. A US stock can trade below US$10 because it is still early-stage and unprofitable, has been heavily sold off, or faces serious business and regulatory challenges. “Cheap” can reflect opportunity, but it can also signal genuine distress. The better question is not “Is it under US$10?” but “What am I actually buying?” That means understanding the business model, growth catalysts, cash burn and dilution risk before clicking buy. Marqeta and MeiraGTx are useful case studies of how sub‑US$10 growth stocks can offer real potential but also substantial risk for Malaysians.
Marqeta Stock Analysis: Fintech Infrastructure with an AI Fraud-Fighting Catalyst
Marqeta operates in digital payments, providing a modern card issuing platform plus processing and program management for companies that want configurable payment cards. Instead of building this infrastructure from scratch, fintechs and platforms can plug into Marqeta’s technology to launch cards quickly and manage transactions at scale. A key growth catalyst is its upgraded Real-Time Decisioning (RTD) offering, which now integrates an AI-powered risk score designed to flag transaction threats at the point of authorization. The model is trained on proprietary transaction data and analyses over 300 real-time attributes against historical behaviour to detect risk signatures, helping cut fraud while reducing false declines. This AI tool sits within Marqeta’s broader RiskControl suite, which includes KYC, 3D Secure and dispute management. As global payment fraud is expected to keep rising, a smarter, adaptive risk engine strengthens Marqeta’s value to customers and could support its positioning among growth stocks under 10 for Malaysian investors seeking US tech exposure.
MeiraGTx Growth Potential: A Focused Gene Therapy Bet, Not a Sure Thing
MeiraGTx is a clinical-stage biotechnology company developing gene therapies for serious diseases, particularly ocular and neurodegenerative conditions. Its recent move to reacquire all interests in botaretigene sparoparvovec (bota‑vec), a gene therapy for X-linked retinitis pigmentosa (XLRP), from Johnson & Johnson is a major strategic swing. Under the asset purchase agreement, MeiraGTx will make an upfront cash payment of USD 25 million (approx. RM117 million), with additional milestone payments tied to US regulatory approval and sales, plus royalties from 2029. The company already manufactures the product and plans to pursue regulatory approvals in the US, EU and Japan, targeting a possible launch in 2027. Phase 3 LUMEOS data showed clinically meaningful improvements in retinal sensitivity and visual function, even though the primary mobility endpoint missed statistical significance. For Malaysian investors looking at US biotech growth stocks under 10, MeiraGTx offers clear upside if approvals and commercialization succeed—but the path remains high risk.
Key Risks: Profitability Timelines, Regulation, Customer Dependence and Capital Needs
Both Marqeta and MeiraGTx illustrate why low share prices can hide complex risks. As growth stocks, neither is primarily valued on today’s profits but on expectations of future cash flows. That means long profitability timelines, where any slowdown in revenue growth or rising costs can hit sentiment hard. In Marqeta’s case, its card issuing and risk products sit inside heavily regulated payments and banking ecosystems. Changes in compliance rules or card network policies could affect margins and operations, as could over-reliance on a few large platform customers. MeiraGTx faces classic biotech risks: stringent regulatory scrutiny across the US, EU and Japan, binary outcomes around approval, and the need to fund expensive trials and commercialization. The upfront payment and future milestones for bota‑vec add to capital demands. Malaysians buying such US tech and biotech stocks must accept that dilution from new share issuance is a real possibility if external funding is needed.
A Simple Checklist for Malaysians – and How to Access These US Stocks
Before buying any “cheap” US growth stock, Malaysian retail investors can run a simple four-point checklist. First, revenue growth: is the top line growing consistently, and what drives that growth? Second, cash burn: how much cash is the company consuming each quarter relative to its balance, and how long is its runway? Third, competitive moat: for Marqeta, that means unique fintech infrastructure and AI risk tools; for MeiraGTx, proprietary gene therapy platforms and trial data. Fourth, dilution risk: does the business model require frequent capital raises? Accessing US tech and biotech stocks from Malaysia typically involves opening an account with an international brokerage that offers US market access, then funding in foreign currency. Always factor in FX conversion spreads, trading commissions, custody or platform fees, and the impact of US dollar movements on your returns. Treat sub‑US$10 names as high-risk satellites within a diversified global portfolio, not core holdings.